- If approved, metreleptin would be the first medication available in the EU to treat generalized and partial lipodystrophies - More than 100 patients are currently treated with metreleptin via a ...
DUBLIN, Ireland, and Boston MA, October 17, 2022, Amryt (Nasdaq: AMYT), a global, commercial-stage biopharmaceutical company dedicated to acquiring, developing and commercializing novel treatments for ...
DUBLIN, Ireland, and Boston MA, March 23, 2021, Amryt (Nasdaq: AMYT, AIM: AMYT), a global, commercial-stage biopharmaceutical company focussed on acquiring, developing and commercializing novel ...
VANCOUVER, British Columbia and CAMBRIDGE, Mass., June 12, 2017 (GLOBE NEWSWIRE) -- Novelion Therapeutics Inc. (NASDAQ:NVLN), a biopharmaceutical company dedicated to developing new standards of care ...
Metreleptin and Lipodystrophy Data Presented at the International Meeting of Pediatric Endocrinology
VANCOUVER, British Columbia and CAMBRIDGE, Mass., Sept. 15, 2017 (GLOBE NEWSWIRE) -- Novelion Therapeutics Inc. (NASDAQ:NVLN), a biopharmaceutical company dedicated to developing new standards of care ...
Novelion Therapeutics' (NVLN +1%) European subsidiary files a Marketing Authorization Application (MAA) seeking approval for Orphan Drug-tagged metreleptin as replacement therapy to treat ...
Amryt Receives Reimbursement Approval from the French Ministry of Social Affairs and Health for Myalepta® (metreleptin) Amryt Receives Reimbursement Approval from the French Ministry of Social Affairs ...
DUBLIN, Ireland, and Boston MA, January 20, 2021, Amryt (Nasdaq: AMYT, AIM: AMYT), a global, commercial-stage biopharmaceutical company dedicated to acquiring, developing and commercializing novel ...
"Lipodystrophy Syndrome Market Insight, Epidemiology and Market Forecast - 2032"The lipodystrophy syndrome market is experiencing significant expansion, driven by increasing disease awareness, rising ...
VANCOUVER, B.C., Dec. 21, 2016 (GLOBE NEWSWIRE) -- Novelion Therapeutics Inc. (NVLN.TO) (NVLN.TO), a biopharmaceutical company dedicated to developing new standards of care for individuals living with ...
Amryt Receives Reimbursement Approval from the French Ministry of Social Affairs and Health for Myalepta® (metreleptin) DUBLIN, Ireland, and Boston MA, March 22, 2021, Amryt (Nasdaq: AMYT, AIM: AMYT), ...
DUBLIN, Ireland, and Boston MA, March 22, 2021, Amryt (Nasdaq: AMYT, AIM: AMYT), a global, commercial-stage biopharmaceutical company dedicated to acquiring, developing and commercializing novel ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback